Abstract: The present invention relates to a primer-probe composition, a kit, and a detection method. The primer-probe composition is selected from one group of group (i) to group (ix), and the kit comprises the primer-probe composition. According to the present invention, the detection of AKR1C3 RNA content in an ex vivo sample of a patient can be achieved.

Abstract: Described is to a primer-probe composition, a kit, and a detection method. The primer-probe composition is selected from one group of group (i) to group (ix), and the kit includes the primer-probe composition. As described, the detection of AKRIC3 RNA content in an ex vivo sample of a patient can be achieved.

Abstract: An AKR1C3 detection method, and a diagnostic kit for detecting AKR1C3 and use thereof. The AKR1C3 detection method includes the following steps: treating a formalin-fixed paraffin-embedded human tissue specimen sequentially using an organic solvent, an alcohol, and water; performing antigen retrieval on the treated formalin-fixed paraffin-embedded human tissue specimen in the presence of an antigen retrieval solution; co-incubating the antigen-retrieved formalin-fixed paraffin-embedded human tissue specimen with a blocking buffer to block a non-specific antigen; mixing the blocked formalin-fixed paraffin-embedded human tissue specimen with a certain concentration of AKR1C3 monoclonal antibody solution for primary antibody incubation, and mixing the primary antibody-incubated formalin-fixed paraffin-embedded human tissue specimen with a certain concentration of a secondary antibody solution for secondary antibody incubation.

Abstract: Described is a method for associating with the expression level of an AKR1C3 enzyme via the content of prostaglandin, and the use of screening for drug administration. In particular, the content of prostaglandin is measured to associate with the expression level of the AKR1C3 enzyme in a biological sample; and the change in the content and the change rate of the content of prostaglandin before and after administering interfering drugs are measured to associate with the expression level of the AKR1C3 enzyme in the biological sample.